HLCS
Basic information
Region (hg38): 21:36748626-36990236
Links
Phenotypes
GenCC
Source:
- holocarboxylase synthetase deficiency (Definitive), mode of inheritance: AR
- holocarboxylase synthetase deficiency (Definitive), mode of inheritance: AR
- holocarboxylase synthetase deficiency (Strong), mode of inheritance: AR
- holocarboxylase synthetase deficiency (Supportive), mode of inheritance: AR
- holocarboxylase synthetase deficiency (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Holocarboxylase synthetase deficiency | AR | Biochemical | Biotin therapy can be beneficial to treat severe manifestations (which can include findings such as alopecia, keratoconjunctivitis, lactic acidosis, perioral erosions, and seizures), though the degree of response varies | Biochemical; Dermatologic; Neurologic; Ophthalmologic | 6798072; 6794361; 6114319; 6790844; 6133032; 8319716; 7842009; 8817339; 9128289; 10190325; 11735028; 12124727; 12855220; 16134170; 16231399; 20095979; 21874615 |
ClinVar
This is a list of variants' phenotypes submitted to
- Holocarboxylase_synthetase_deficiency (849 variants)
- not_provided (98 variants)
- Inborn_genetic_diseases (89 variants)
- not_specified (61 variants)
- HLCS-related_disorder (7 variants)
- Familial_isolated_deficiency_of_vitamin_E (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the HLCS gene is commonly pathogenic or not. These statistics are base on transcript: NM_001352514.2. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 344 | 353 | ||||
missense | 22 | 227 | 40 | 299 | ||
nonsense | 26 | 31 | 57 | |||
start loss | 0 | |||||
frameshift | 32 | 59 | 95 | |||
splice donor/acceptor (+/-2bp) | 21 | 23 | ||||
Total | 67 | 133 | 239 | 384 | 4 |
Highest pathogenic variant AF is 0.000216837
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
HLCS | protein_coding | protein_coding | ENST00000399120 | 9 | 239348 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.92e-8 | 0.966 | 125672 | 0 | 76 | 125748 | 0.000302 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.148 | 395 | 403 | 0.979 | 0.0000241 | 4746 |
Missense in Polyphen | 120 | 135 | 0.88891 | 1585 | ||
Synonymous | -1.07 | 188 | 170 | 1.10 | 0.0000120 | 1458 |
Loss of Function | 2.08 | 17 | 29.1 | 0.584 | 0.00000145 | 356 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000778 | 0.000778 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000762 | 0.000761 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000300 | 0.000264 |
Middle Eastern | 0.000762 | 0.000761 |
South Asian | 0.000392 | 0.000294 |
Other | 0.000489 | 0.000489 |
dbNSFP
Source:
- Function
- FUNCTION: Post-translational modification of specific protein by attachment of biotin. Acts on various carboxylases such as acetyl- CoA-carboxylase, pyruvate carboxylase, propionyl CoA carboxylase, and 3-methylcrotonyl CoA carboxylase.;
- Pathway
- Biotin metabolism - Homo sapiens (human);Biotin Metabolism;Multiple carboxylase deficiency, neonatal or early onset form;Biotinidase Deficiency;Biotin transport and metabolism;Metabolism;Metabolism of water-soluble vitamins and cofactors;Metabolism of vitamins and cofactors;biotin-carboxyl carrier protein assembly
(Consensus)
Recessive Scores
- pRec
- 0.251
Intolerance Scores
- loftool
- 0.0681
- rvis_EVS
- -0.59
- rvis_percentile_EVS
- 18.25
Haploinsufficiency Scores
- pHI
- 0.0715
- hipred
- N
- hipred_score
- 0.417
- ghis
- 0.551
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.998
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Hlcs
- Phenotype
Gene ontology
- Biological process
- biotin metabolic process;cell population proliferation;protein biotinylation;histone modification;response to biotin;histone biotinylation
- Cellular component
- chromatin;nuclear lamina;mitochondrion;cytosol;nuclear matrix
- Molecular function
- biotin-[acetyl-CoA-carboxylase] ligase activity;biotin-[methylcrotonoyl-CoA-carboxylase] ligase activity;biotin-[methylmalonyl-CoA-carboxytransferase] ligase activity;biotin-[propionyl-CoA-carboxylase (ATP-hydrolyzing)] ligase activity;protein binding;ATP binding;biotin binding;biotin-protein ligase activity;enzyme binding;protein homodimerization activity